Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial

被引：7
|
作者：
Guttman-Yassky, E. [1 ,9 ]
Bahadori, L. [2 ]
Brooks, L. [3 ]
Clark, K. L. [3 ]
Grindebacke, H. [4 ]
Ho, C. N. [5 ]
Katial, R. [6 ,7 ]
Pham, T. -H. [8 ]
Walton, C. [3 ]
Datto, C. J. [2 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Cambridge, England
[4] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden
[5] AstraZeneca, Patient Ctr Sci, BioPharmaceut Med, Gaithersburg, MD USA
[6] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA
[7] Natl Jewish Hlth, Denver, CO USA
[8] AstraZeneca, Translat Sci & Expt Med, Early Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA
[9] Icahn Sch Med Mt Sinai, Kimberly & Er J Waldman Dept Dermatol, 1425 Madison Ave,Box 1047, New York, NY 10029 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 10期
关键词：
EFFICACY; SAFETY;
D O I：
10.1111/jdv.19195
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E1211 / E1214
页数：4
相关论文
共 50 条
  • [21] Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary
    Guttman-Yassky, Emma
    Bahadori, Lila
    Brooks, Laura
    Clark, Ken L.
    Grindebacke, Hanna
    Ho, Calvin N.
    Katial, Rohit
    Pham, Tuyet-Hang
    Walton, Claire
    Datto, Catherine J.
    IMMUNOTHERAPY, 2024, 16 (10) : 641 - 648
  • [22] SARILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY
    Huizinga, T. W.
    Kivitz, A. J.
    Rell-Bakalarska, M.
    Fleischmann, R. M.
    Jasson, M.
    Radin, A. R.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 60 - 60
  • [23] Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
    Bissonnette, R.
    Haydey, R.
    Rosoph, L. A.
    Lynde, C. W.
    Bukhalo, M.
    Fowler, J. F.
    Delorme, I.
    Gagne-Henley, A.
    Gooderham, M.
    Poulin, Y.
    Barber, K.
    Jenkin, P.
    Landells, I.
    Pariser, D. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 403 - 410
  • [24] Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
    Genovese, Mark C.
    Kivitz, Alan J.
    Simon Campos, J. Abraham
    Rell-Bakalarska, Maria
    Fleischmann, Roy M.
    Jasson, Martine
    Radin, Allen R.
    Huang, Xiaohong
    Huizinga, Tom W. J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4041 - 4042
  • [25] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg, A.
    Blauvelt, A.
    Guttman-Yassky, E.
    Worm, M.
    Lynde, C.
    Lacour, J. -P.
    Spelman, L.
    Katoh, N.
    Saeki, H.
    Poulin, Y.
    Lesiak, A.
    Kircik, L.
    Cho, S. H.
    Herranz, P.
    Cork, M. J.
    Peris, K.
    Steffensen, L. A.
    Bang, B.
    Kuznetsova, A.
    Jensen, T. N.
    osterdal, M. L.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
  • [26] Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase3trial
    Cadot, Pierre
    Hensel, Patrick
    Bensignor, Emmanuel
    Hadjaje, Celine
    Marignac, Genevieve
    Beco, Luc
    Fontaine, Jacques
    Jamet, Jean-Francois
    Georgescu, Gabriela
    Campbell, Karen
    Cannon, Andrea
    Osborn, Sarah C.
    Messinger, Linda
    Gogny-Goubert, Michel
    Dubreuil, Patrice
    Moussy, Alain
    Hermine, Olivier
    VETERINARY DERMATOLOGY, 2011, 22 (06) : 554 - 564
  • [27] Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: A randomized, double-blind controlled explorer trial
    Liu, Xiaochun
    Luo, Yang
    Chen, Xingyu
    Wu, Mingyang
    Xu, Xiaoqiang
    Tian, Jingru
    Gao, Yingxia
    Zhu, Jun
    Wang, Zhifeng
    Zhou, Yuan
    Zhang, Yu
    Wang, Xiaokai
    Li, Wei
    Lu, Qianjin
    Yao, Xu
    ALLERGY, 2024,
  • [28] EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Zhao, Yan
    Wu, Liming
    Lu, Qianjin
    Gao, Xinghua
    Zhu, Xiaohong
    Yao, Xu
    Li, Linfeng
    Li, Wei
    Ding, Yangfeng
    Song, Zhiqiang
    Liu, Lingling
    Dang, Ningning
    Zhang, Chunlei
    Liu, Xiaoming
    Gu, Jun
    Wang, Jinyan
    Geng, Songhai
    Liu, Qunazhong
    Guo, Yifeng
    Lv, Dong
    Ren, Gong
    Yang, Xiumin
    Deng, Danqi
    Li, Shanshan
    Han, Xiuping
    Biao, Shuzhen
    Zheng, Min
    Dong, Li
    Su, Huijuan
    Bai, Lili
    O'Malley, John T.
    Luo, Junxiang
    Zhang, Jianzhong
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 58 - 58
  • [29] Achieving an itch-free state with upadacitinib: a post hoc analysis of data from a phase IIb randomized, double-blind, placebo-controlled trial in moderate-to-severe atopic dermatitis
    Silverberg, J. I.
    Reich, K.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Teixeira, H.
    Guttman-Yassky, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E98 - E98
  • [30] Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial
    Berth-Jones, J
    Takwale, A
    Tan, E
    Barclay, G
    Agarwal, S
    Ahmed, I
    Hotchkiss, K
    Graham-Brown, RAC
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) : 324 - 330
12345